Conditional sentence

Airdoc Technology (2251.HK) Receives EU CE MDR Certification, Securing Market Access in Multiple Countries

Retrieved on: 
Tuesday, January 30, 2024
Diabetes, Certification, Patient, MDR, Incidence, Health, Diagnosis, Risk, International, Diabetic retinopathy, Disability, News, Travel, Medical device regulation, Conditional sentence, Finance, Prediabetes, National Medical Products Administration, CE, Prevalence, Medical device

Airdoc Technology (2251.HK) Receives EU CE MDR Certification, Securing Market Access in Multiple Countries

Key Points: 
  • Airdoc Technology (2251.HK) Receives EU CE MDR Certification, Securing Market Access in Multiple Countries
    On January 8th, Airdoc Technology announced that its Airdoc-AIFUNDUS (1.0) has recently obtained the CE marking ("CE MDR") as per the Medical Device Regulation, allowing comprehensive market entry into 27 EU countries, including Belgium, Germany, Italy, France, and more.
  • AI-FUNDUSCAMERA-P has obtained regulatory approval or registration in Indonesia, South Africa, the United Arab Emirates, and Thailand.
  • The company's self-developed AI-FD16 series of fundus cameras is China's first fully automatic, self-service, portable fundus camera to be approved for market release.
  • With market access permits obtained from various countries and regions, China's original AI technology is set to travel across the globe, benefiting local residents and making health ubiquitous.

Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer

Retrieved on: 
Monday, January 29, 2024
Drug, Conditional sentence, Spark Therapeutics, Translation, Patient, Therapy, Employment, Paratriathlon, AAV, Universities of Lille, Innovation, Pfizer, LUNA, AMD, Adverum Biotechnologies, Drug discovery, CNS, Pharmaceutical industry

REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Romuald “Romu” Corbau, Ph.D., has joined Adverum as the company’s chief scientific officer.

Key Points: 
  • REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Romuald “Romu” Corbau, Ph.D., has joined Adverum as the company’s chief scientific officer.
  • “On behalf of the entire team at Adverum, I am delighted to welcome Dr. Corbau as the newest member of our executive leadership team.
  • Dr. Corbau joins Adverum from GenEdit, where he served as Chief Scientific Officer.
  • Prior to joining GenEdit, Dr. Corbau progressed from Vice President of Research to Chief Scientific Officer at Freeline, a clinical stage company developing AAV-vector mediated systemic gene therapies for chronic diseases.

Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones

Retrieved on: 
Tuesday, January 23, 2024
CMC, LOS, Dialysis, Patient, Therapy, International Society of Nephrology, NKF, National Kidney Foundation, ATP, Agency, Hyperphosphatemia, American Journal, Acute kidney injury, Nephrology, Clutch (eggs), ISN, Trial of the century, Society, Kidney disease, Chronic kidney disease, Water, NDA, European Renal Association, HIV/AIDS, CKD, Conditional sentence, Heart, FDA, Tablet, ERA, Letter, Patent, International Society, Mitochondrial disease, Diabetes, Physician, Pharmaceutical industry

LOS ALTOS, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today issued a letter to shareholders.

Key Points: 
  • As I sit down to write this letter, I am filled with a profound sense of gratitude and excitement, energized for the year ahead.
  • In this letter, I am pleased to recap for you another year of great accomplishments.
  • We’ve made significant advancements in our clinical programs which will propel us to new heights in 2024.
  • I would like to express my deep appreciation to the physician investigators, study participants, and especially to our dedicated Unicycive employees.

Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID

Retrieved on: 
Monday, January 22, 2024
Conditional sentence, Fibromyalgia, Patient, Therapy, Orthostatic intolerance, Partnership, Fatigue, Chronic fatigue syndrome, Celecoxib, Valaciclovir, FDA, Pharmaceutical industry

ATLANTA, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced plans for advancing IMC-2 (combination of valacyclovir and celecoxib) as a treatment for the fatigue, orthostatic intolerance and other symptoms associated with LC, also known as post-acute sequelae of SARS-CoV-2 infection (“PASC”). The Company is targeting the initiation of a Phase 2 program in the second half of 2024, with data expected in 2025.

Key Points: 
  • The Company is targeting the initiation of a Phase 2 program in the second half of 2024, with data expected in 2025.
  • “We believe the profound unmet medical need associated with LC symptoms provides a unique and timely opportunity for Virios to advance our combination therapy, IMC-2,” said Greg Duncan, Chairman and CEO of Virios Therapeutics.
  • “There are currently no FDA-approved LC treatments, thus IMC-2 has potential to be one of the first therapies for addressing LC symptoms.
  • In addition, we have received input from the FDA on development requirements and key endpoints associated with advancing IMC-2 into Phase 2 development as a treatment for LC symptoms.

Emerging Trends in the Medical Refrigerators Industry, 2023-2028: Global Analysis Featuring Profiles of Leading Players Including Thermo Fisher, Blue Star, and Standex International Corporation - ResearchAndMarkets.com

Retrieved on: 
Monday, January 29, 2024
Biotechnology, Health, Medical Supplies, Diabetes, Conditional sentence, Research, Patient, Hospital, Pharmacy, Syringe, Temperature, Others, Anemia, Blood, Combustibility and flammability, School, Tissue, Cancer, Vaccination, Sale, Plasma, COVID-19, Antibody, Medicine, Laboratory, Prevalence, Temperature control, Plant, Humidity, Vaccine, Cell, Growth, Pharmaceutical industry

As a result, there is a rising need for medical refrigerators with sophisticated features including temperature, humidity, and alarm controls.

Key Points: 
  • As a result, there is a rising need for medical refrigerators with sophisticated features including temperature, humidity, and alarm controls.
  • Therefore, the burgeoning prevalence of chronic diseases has led to a greater focus on medical refrigerators, thus, boosting the overall market growth.
  • By Design Type: The report identifies four segments on the basis of design type: Countertop Medical Refrigerators, Undercounter Medical Refrigerators, Explosion-Proof Refrigerators, and Flammable Material Storage Medical Refrigerators.
  • The global medical refrigerators market is highly competitive and fragmented, with several players operating on a regional and global scale.

With New Community Garden and Food Pharmacy, Tampa General Hospital and the City of Tampa Advance Health and Wellness Among Area Residents

Retrieved on: 
Monday, January 29, 2024
Diabetes, Obesity, Patient, Food, Health, Hypertension, City, Life, Culture, Partnership, Tampa General Hospital, Medicine, Behavior, Quality of life, TGH, Conditional sentence, Vegetable, Workforce, Prediabetes, Community gardening, Motivation, Nursing

TAMPA, Fla. , Jan. 29, 2024 /PRNewswire/ -- Marking a significant milestone in the TampaWell initiative, Tampa General and the City of Tampa officially welcomed residents to enjoy the benefits of healthy eating with support from a brand-new community garden and food pharmacy. John Couris, president and CEO of Tampa General, and Tampa Mayor Jane Castor were joined by community leaders and area residents to cut the ribbon on the new TampaWell Community Garden and Food Pharmacy, both conveniently located at TGH Family Care Center Healthpark, which serves one of the most food insecure neighborhoods in the region.

Key Points: 
  • "With this new community garden and food pharmacy, we're working to ensure that residents of this community can benefit from nutritious foods, contributing to better health and a greater quality of life."
  • TampaWell was activated by Tampa General Hospital in 2022, in partnership with the City of Tampa.
  • It was the start of a wellness revolution in Tampa Bay with the goal of making Tampa the ultimate wellness destination in the United States.
  • The TampaWell Community Garden and Food Pharmacy is next to the TGH Family Care Center Healthpark, located at 5802 North 30th Street, Tampa, Florida.

DeRUCCI Smart Mattress Wins TWICE CES Picks Award 2024

Retrieved on: 
Tuesday, January 23, 2024
Retail, Consumer Electronics, IOT (Internet of Things), Technology, Home Goods, Artificial Intelligence, The Wall Street Journal, Peter Hancock (professor), Heart rate, Sleep, Research, Aromatherapy, Renni Rucci, Artificial intelligence, Health, Temperature, Diet, ABP, CBS-TV, LaTeX, Electronics, Business Insider, Algorithm, TechRadar, TWICE, News, Safety, Conditional sentence, ABC-TV, CES, Yahoo!, CNET, Exercise, Consumer electronics, Internet of things, Consumer Electronics Show

“CES seemed as busy as ever this year and the awards matched this. This year, we received a record amount of entries, and the quality across the board was incredible. Winners should be extremely proud of their achievement -- their product showed true innovation and hugely impressed our judging panel,” said the TWICE Awards’ editorial team.

Key Points: 
  • The DeRUCCI Group https://www.derucci.com , a leading public company and sleep technology brand, announced today that the DeRUCCI T11 Pro Smart Mattress has won the coveted 2024 CES Picks Awards in the TWICE consumer electronics category.
  • DeRUCCI was selected as a TWICE CES 2024 Picks winner based on the impact expected on the Consumer Electronics industry.
  • The TWICE CES 2024 Picks Award recognizes the very best products and solutions on display at CES 2024, with hundreds of products and solutions considered.
  • “Thank you to the entire TWICE CES 2024 Picks Award editorial team!”
    The CES 2024 Picks Award caps off a successful week at the CES Show in Las Vegas, where DeRUCCI was also awarded with the CES 2024 Innovation Awards in two categories and the BIG Innovation Award, and was also featured in top international publications and shows, including the Wall Street Journal, CNET, Forbes, Business Insider, T3, and Techradar, Yahoo!

Noom GLP-1 Companion to Add “Muscle Defense” to Promote Safer GLP-1 Use

Retrieved on: 
Friday, January 19, 2024
Apps, Applications, Technology, Mobile, Wireless, Fitness & Nutrition, Health Technology, Telemedicine, Virtual Medicine, Health, Pharmaceutical, General Health, Well, Mortality, Obesity, Bone density, Patient, Facial muscles, Overalls, Sarcopenic obesity, MD, Interactivity, Multimedia, Diet, Partnership, Comprehensive, Atrophy, History, Fitness, Behavior, Risk, FACP, Medicine, Conditional sentence, Insulin resistance, Dietary supplement

Noom GLP-1 Companion with Muscle Defense is aimed at helping GLP-1 users navigate one of the most problematic concerns surrounding GLP-1 use today — muscle mass loss.

Key Points: 
  • Noom GLP-1 Companion with Muscle Defense is aimed at helping GLP-1 users navigate one of the most problematic concerns surrounding GLP-1 use today — muscle mass loss.
  • To address this major concern of lost muscle mass while taking GLP-1s, Noom today announced its partnership with FitOn to launch Muscle Defense within its most recent offering: Noom GLP-1 Companion .
  • Noom GLP-1 Companion with Muscle Defense provides the protein-tracking, resistance training, behavior change, and expert guidance needed to have the best outcomes while taking a GLP-1.
  • Noom GLP-1 Companion with Muscle Defense will begin rolling out in the spring.

Global IVD Quality Control Industry Report 2023-2030: Third-Party Quality Controls in High Demand, Fueling Market Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 17, 2024
Health, Biotechnology, Conditional sentence, Hepatitis, Hospital, IVD, Syphilis, Gonorrhea, Infection, WHO, Quality control, Vertically transmitted infection, Fungal infection, STI, Birth, POC, Trichomoniasis, Diagnosis, Prevalence, Growth, Pharmaceutical industry

The "IVD Quality Control Market by Offering, Application, and End User - Global Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "IVD Quality Control Market by Offering, Application, and End User - Global Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The IVD quality control market is expected to reach $2.19 billion by 2030, at a CAGR of 4.3% from 2023 to 2030.
  • Among the offering, in 2023, the quality control products segment is estimated to account for the largest share of the IVD quality control market.
  • Among the application, in 2023, the infectious diseases segment is estimated to account for the largest share of the IVD quality control market.

GlobalData report highlights staggering economic costs for South Carolina of $7.4 billion due to obesity

Retrieved on: 
Wednesday, January 17, 2024
Labor, Fitness & Nutrition, Public Policy, Government, Healthcare Reform, Business, Professional Services, Health, State, Local, General Health, Welfare, Conditional sentence, Woman, Death, Medicaid, Weight loss, Culture, Medicare, Insurance, Federation, Eli Lilly and Company, Parity, Disease, DSM-IV codes, Workforce, Head, Overweight, GlobalData, Education, Pharmaceutical industry

GlobalData’s report, ‘ Obesity’s Impact on South Carolina's Economy and Labor Force ,’ analyzes the economic and workforce implications of obesity in the State of South Carolina, as well as the impact on state tax revenue collections and costs.

Key Points: 
  • GlobalData’s report, ‘ Obesity’s Impact on South Carolina's Economy and Labor Force ,’ analyzes the economic and workforce implications of obesity in the State of South Carolina, as well as the impact on state tax revenue collections and costs.
  • In South Carolina, approximately one-third of adults are classified as having obesity (35.0%), and another third have overweight (34.8%) in 2022.
  • Employers in South Carolina paid an extra $907 million in higher medical expenditures for health complications attributed to obesity and overweight.
  • The federal government also spent an estimated $1.7 billion more on Medicare and Medicaid for South Carolina residents.